7 February 2025
Cancers | Highly Viewed Papers in 2024 and Hot Topic Special Issues on Cancer Drug Development
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are delighted to share some highly viewed papers on cancer drug development that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs”
by Virginia Metrangolo and Lars H. Engelholm
Cancers 2024, 16(2), 447; https://doi.org/10.3390/cancers16020447
Available online: https://www.mdpi.com/2072-6694/16/2/447
“Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer”
by Xin Gu and Tamara Minko
Cancers 2024, 16(8), 1589; https://doi.org/10.3390/cancers16081589
Available online: https://www.mdpi.com/2072-6694/16/8/1589
“Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989”
by Othman Al Musaimi
Cancers 2024, 16(5), 1032; https://doi.org/10.3390/cancers16051032
Available online: https://www.mdpi.com/2072-6694/16/5/1032
“Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review”
by Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, Mahima Bansode, Kratika Khunteta, Priyanka Vijay Sonar, Ameya Hebale, Vaishnavi Salokhe and Birandra Kumar Sinha
Cancers 2024, 16(4), 680; https://doi.org/10.3390/cancers16040680
Available online: https://www.mdpi.com/2072-6694/16/4/680
“Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma”
by Ali Al Sbihi, Maryam Alasfour and Georgios Pongas
Cancers 2024, 16(4), 827; https://doi.org/10.3390/cancers16040827
Available online: https://www.mdpi.com/2072-6694/16/4/827
“DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance”
by Han Zhang, Paula M. Mañán-Mejías, Hannah N. Miles, Andrea A. Putnam, Leonard R. MacGillivray and William A. Ricke
Cancers 2024, 16(6), 1131; https://doi.org/10.3390/cancers16061131
Available online: https://www.mdpi.com/2072-6694/16/6/1131
Special Issues:
|
“Drug Targeting Therapy in Multiple Myeloma” |
“Recent Advances in PROteolysis TArgeting Chimeras (PROTACs)” |
|
|
|
|
“Understanding the Complexities of Anticancer Drugs Resistance” |
“Drug Repurposing and Reformulation for Cancer Treatment: 2nd Edition” |
|
|
|
You are invited to view and submit relevant papers to the journal Cancers at the following link: https://www.mdpi.com/journal/cancers.
Cancers Editorial Office